Imatinib Completed Phase 2 Trials for refractory Small cell lung cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00052949Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer